Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 in moderate to severe rheumatoid arthritis with inadequate response to targeted therapies
MOH_2021-07-28_010073Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABBV-154 in rheumatoid arthritis (RA) (5 arms), sponsored by AbbVie Inc. Primary endpoint: Safety and efficacy. Started Jul 2021; status: active, not recruiting.
02
Drugs
ABBV-154
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2021-07-28_010073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-28_010073.